Pfizer (NYSE: PFE) was a stock on the move Wednesday, and not because of any news generated by the healthcare company. Reports of a meeting between Pfizer's leader and an activist investor breathed life into the stock, which closed the day more than 3% higher in price. That gain well exceeded the 0.7% increase of the S&P 500 index.
An activist meeting is apparently imminent
Late afternoon on Tuesday, the Financial Times (FT) published an article stating that Pfizer CEO Albert Bourla plans to meet that activist investor, Starboard Value. Citing unnamed "people familiar with the matter," the business newspaper wrote that Bourla is to engage in talks with Starboard, accompanied by at least one other member of Pfizer's board of directors.
That report came mere days after The Wall Street Journal broke the news that Starboard had taken a stake worth around $1 billion in the American pharmaceutical giant. That would give it a roughly 0.6% holding in the company. Although this is not a major stake, it is sufficient for Starboard to loudly and publicly advocate for change -- the typical method of operation for activist investors.
According to the FT's sources, Starboard has created an "extensive" slide deck presentation on its ideas for modifications of strategy at Pfizer. However, it has yet to release it.
Post-coronavirus fatigue
While Pfizer is a powerful company, it hasn't managed to shake its reputation as something of an also-ran following its great success as the co-developer of the coronavirus vaccine Comirnaty (in partnership with German biotech BioNTech) earlier this decade. The company's post-pandemic fundamentals at times haven't been impressive; investors will be hoping that if a Pfizer/Starboard summit takes place, it produces good ideas for the former's approach going forward.
Don’t miss this second chance at a potentially lucrative opportunity
Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.
On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:
Amazon: if you invested $1,000 when we doubled down in 2010, you’d have $20,579!*
Apple: if you invested $1,000 when we doubled down in 2008, you’d have $42,710!*
Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $389,239!*
Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.
*Stock Advisor returns as of October 7, 2024
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool recommends BioNTech Se. The Motley Fool has a disclosure policy.
Why Pfizer Stock Popped Today was originally published by The Motley Fool